secwatch.observer — SEC 8-K summary
======================================

Issuer:     60 DEGREES PHARMACEUTICALS, INC. (SXTP)
CIK:        0001946563
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0001213900-24-068942
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

60 Degrees Pharma grants UK right of reference to ARAKODA NDA for SJ733 Phase IIb trial
--------------------------------------------------------------------------------

- Granted University of Kentucky right of reference to ARAKODA NDA for FDA review of data supporting SJ733 Phase IIb study.
- Phase IIb will combine SJ733 (oral ATP4 inhibitor) with tafenoquine for radical cure of Plasmodium vivax malaria.
- Study funded by Global Health Innovative Technology Fund; Eisai managing trial material manufacturing and non-clinical studies.
- 60 Degrees Pharma will supply tafenoquine and placebos as study drugs for the trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1946563/000121390024068942/0001213900-24-068942-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1946563/000121390024068942/ea0211411-8k_60degrees.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-068942

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer